Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G10 | O15496 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.31 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ANPEP | P15144 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.30 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27128098 | 1.00 | PLA2G10 (0.33) | PLA2G10SMN1; SMN2ALDH1A1LMNAS1PR4 | |
| SCHEMBL19859526 | 0.79 | SMN1; SMN2 (0.31) | SMN1; SMN2 | |
| SCHEMBL19859530 | 0.79 | SMN1; SMN2 (0.31) | SMN1; SMN2 | |
| SCHEMBL27122522 | 0.77 | MMP1 (0.41) | SMN1; SMN2 | |
| SCHEMBL26965318 | 0.77 | MMP1 (0.41) | SMN1; SMN2 | |
| SCHEMBL27127864 | 0.74 | LMNA (0.43) | SMN1; SMN2LMNAKMT2APOLB | |
| SCHEMBL26965342 | 0.74 | LMNA (0.43) | SMN1; SMN2LMNAKMT2APOLB | |
| SCHEMBL26965364 | 0.71 | CNR1 (0.32) | ALDH1A1LMNAFOLH1MMEL1 | |
| SCHEMBL27121679 | 0.71 | CNR1 (0.32) | ALDH1A1LMNAFOLH1MMEL1 | |
| SCHEMBL24387886 | 0.70 | SCN10A (0.42) | SMN1; SMN2ALDH1A1LMNAMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230406860-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | AMGEN INC. | 2023-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230406860-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | KRAS, NRAS, HRAS | PLA2G10 2367/4885SMN1; SMN2 1008/4885ALDH1A1 1457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.